Candida albicans and Candida glabrata: global priority pathogens
- PMID: 38832801
- PMCID: PMC11332356
- DOI: 10.1128/mmbr.00021-23
Candida albicans and Candida glabrata: global priority pathogens
Abstract
SUMMARYA significant increase in the incidence of Candida-mediated infections has been observed in the last decade, mainly due to rising numbers of susceptible individuals. Recently, the World Health Organization published its first fungal pathogen priority list, with Candida species listed in medium, high, and critical priority categories. This review is a synthesis of information and recent advances in our understanding of two of these species-Candida albicans and Candida glabrata. Of these, C. albicans is the most common cause of candidemia around the world and is categorized as a critical priority pathogen. C. glabrata is considered a high-priority pathogen and has become an increasingly important cause of candidemia in recent years. It is now the second most common causative agent of candidemia in many geographical regions. Despite their differences and phylogenetic divergence, they are successful as pathogens and commensals of humans. Both species can cause a broad variety of infections, ranging from superficial to potentially lethal systemic infections. While they share similarities in certain infection strategies, including tissue adhesion and invasion, they differ significantly in key aspects of their biology, interaction with immune cells, host damage strategies, and metabolic adaptations. Here we provide insights on key aspects of their biology, epidemiology, commensal and pathogenic lifestyles, interactions with the immune system, and antifungal resistance.
Keywords: Candida albicans; Candida glabrata; Nakaseomyces glabratus; WHO fungal priority list; antifungal resistance; commensalism; diagnostics; epidemiology; host response; pathogenicity.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Two unlike cousins: Candida albicans and C. glabrata infection strategies.Cell Microbiol. 2013 May;15(5):701-8. doi: 10.1111/cmi.12091. Epub 2013 Jan 14. Cell Microbiol. 2013. PMID: 23253282 Free PMC article. Review.
-
Candida glabrata (Nakaseomyces glabrata): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List.Med Mycol. 2024 Jun 27;62(6):myae041. doi: 10.1093/mmy/myae041. Med Mycol. 2024. PMID: 38935913 Free PMC article.
-
Six-Year Retrospective Analysis of Epidemiology, Risk Factors, and Antifungal Susceptibilities of Candidiasis from a Tertiary Care Hospital in South China.Microbiol Spectr. 2023 Aug 17;11(4):e0070823. doi: 10.1128/spectrum.00708-23. Epub 2023 Jun 13. Microbiol Spectr. 2023. PMID: 37310269 Free PMC article.
-
Epidemiology of candidemia in Shiraz, southern Iran: A prospective multicenter study (2016-2018).Med Mycol. 2021 May 4;59(5):422-430. doi: 10.1093/mmy/myaa059. Med Mycol. 2021. PMID: 32692816
Cited by
-
Similarities and distinctions in the activation of the Candida glabrata Pdr1 regulatory pathway by azole and non-azole drugs.bioRxiv [Preprint]. 2024 Sep 19:2024.09.19.613905. doi: 10.1101/2024.09.19.613905. bioRxiv. 2024. PMID: 39345512 Free PMC article. Preprint.
-
Simplified J774A.1 macrophage assay for fungal pathogenicity demonstrates non-clinical Nakaseomyces glabratus strains survive better than lab strains.MicroPubl Biol. 2024 Aug 22;2024:10.17912/micropub.biology.001266. doi: 10.17912/micropub.biology.001266. eCollection 2024. MicroPubl Biol. 2024. PMID: 39247786 Free PMC article.
References
-
- Organization WH . 2022. WHO fungal priority pathogens list to guide research, development and public health action. Available from: https://www.who.int/publications/i/item/9789240060241
Publication types
MeSH terms
Substances
Grants and funding
- 13N15714/Bundesministerium für Bildung und Forschung (BMBF)
- MR/N006364/2/Medical Research Council Centre for Medical Mycology (MRC CMM)
- University of Exeter
- 101873, 200208, 215599/Wellcome Trust (WT)
- MR/M026663/2/UKRI | Medical Research Council (MRC)
- 224323/WT_/Wellcome Trust/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- SAS-2015-HKI-LWC/Bundesministerium für Bildung und Forschung (BMBF)
- National Institute for Health and Care Research Exeter Biomedical Research Centre
- 528/20-1/Deutsche Forschungsgemeinschaft (DFG)
- 467 390713860/Deutsche Forschungsgemeinschaft (DFG)
LinkOut - more resources
Full Text Sources
Medical